SlideShare a Scribd company logo
1 of 69
Download to read offline
Primary PCI
Prof A N Patnaik
Dr RAMACHANDRA BARIK
Dr Lalita Nemani
Define
 STEMI only
 Urgent angioplasty(with/out
stenting)- Preferably in ≤90min
 No TLT before or parallel
 Open the infarct—related
 Delayed PCI
PCI After TLT
1.Rescue(REACT/MERLIN/RESCU
E)
2.Facilitated(BRAVE/HERO/CAPI
TAL/WASTE/ASCEND)
Of its kinds
Primary Percutaneus coronary intervention
STEMI
Thygesen K, Alpert JS, White HD, et al. Universal definition of myocardial
infarction. Circulation 2007;116:2634-53.
Today’s evening
• Abbreviating time is everything
1.Best transfer Protocol
2. Reverse Paradox
• PPCI vs. TLT
• Who need it?
• PPCI in Octagenerian
• Set up
1.Your Lab 2.Surgical Back up
Contd......
• Operator skill
• Initial therapy in ICCU
• Radial vs. Femoral
• Optimal anticoagulation
• POBA/ BMS/DES
• Hardware
• IABP/ECMO-When and its role
Contd....
• In cath lab
• After cathlab=ICCU
• Predischarge triage
• Finance
• Take home message
Politician also knows.....time is life
Time is muscle
Every minute counts
Gersh BJ, Stone GW, White HD, et al. Pharmacological facilitation of primary
percutaneous coronary intervention foracute myocardial infarction: is the slope of
the curve the shape of the future? JAMA 2005;293:979-86
Terkelsen CJ, Sorensen JT, Maeng M, et al. Systemdelay
and mortality among
patients with STEMI treated with primary percutaneous
coronary intervention.
JAMA2010;304:763-71.
Primary PCI vs. TLT
Choice
(TIMI)-3 Flow in 95% vs 54%(TLT)
Gersh BJ et al. Pharmacological facilitation of PPCI for STEMI: is
the slope of the curve the shape of the future? JAMA 2005;293:979-86
Stone GW et al. Comparison of angioplasty with stenting,with or without
abciximab, in acute myocardial infarction. N Engl J Med 2002;346:957-66
PCI IS THE
BEST
OPTION
PAMI Trial-1997
POBA provides a small-to-moderate, short-term
clinical advantage over TLT with t-PA.
PPCI when it can be accomplished promptly at experienced
centers, should be considered an excellent alternative
method for myocardial reperfusion.
The investigators and centers participating in the GUSTO
IIb Angioplasty Substudy ,Cleveland Clinic,USA
A 2003 meta-analysis
23 randomized trials
7739 patients
 Reductions in short-term death (7% vs 9%, P 0.0002),
 fatal reinfarction (3% vs 7%, P 0.0001),
 stroke (1% vs 2%, P 0.0004)
Keeley EC et al. Primary angioplasty versus intravenous thrombolytic
therapy foracute myocardial infarction: a quantitative review of 23
randomised trials. Lancet 2003;361:13-20
But TLT is the invaluable in certain conditions because delay in
opening artery causes
• CHF/ readmissions/OPD visits increases
 independently with mortality(HR/OR=1.1)
 detrimental in age<65, presenting within 2 hours
Death+ reinfarction+disabling stroke at 30
days was significantly < PCI in 2 of the
studies, with a trend toward significance in
the underpowered third study
“DIDO=Door-in-door-out=30”
Pretransfer TLT
CAPTIM
WEST
“Number Paradox”
Golden’s Hour:2-3Hrs.
Evidence
Evidence....
Evidence..
• MITRA STUDY(Maximal therapy in AMI)
• SWISS STUDY
• DANAMI II
• SHOCK(Shock)
• NRMI-II(CHF)
Primary Percutaneus coronary intervention
Then what to choose?Then what to choose?
“Reperfusion paradox”
vs
Best transfer protocol
Coordinate...to reduce
Initial management =MONA
Oxygen
 Aspirin
Nitroglycerin
Opioids(Morphine)
Cath lab standard
Adjunctive Antithrombotic
Therapy
• Antiplatlets
• Anticoagulation
Antiplatlets
Antiplatlets
GROUP IIB-IIIA Inhibitors
Anticoagulants
‡The recommended ACT with planned GP IIb/IIIa receptor antagonist treatment is 200 to 250 s.
§The recommended ACT with no planned GP IIb/IIIa receptor antagonist treatment is 250 to 300 s (HemoTec device) or 300
to 350 s (Hemochron device).
Access
No but you better understandNo but you better understand
Primary Percutaneus coronary intervention
Shock
• Killip IV
• Ionotrope optimum
• Control IV fluid
• CPR
• IABP/ECMO
• LVAD
• CABG
IABP but use it!!!!!!!!
• No Δ in infarct size at 3-5 days
• No Δ in all cause death at 6 months
Ohman EM, et al. Use of aortic counterpulsation to improve sustained coronary artery patency during AMI.RCT.
The Randomized IABP Study Group. Circulation 1994.
Stone GW et al, (PAMI-II) Trial Investigators. J Am Coll Cardiol 1997; 29:1459.
Brodie BR et al,IABP, before PPCI reduces catheterization laboratory events in high-risk patients with AMI . Am J
Cardiol 1999
Patel MR,et al. CRISP AMI Trial. JAMA 2011; 306:1329.
Anticoagulation-ACT
Anticoagulation ACT
HEPARIN ONLY 250 to 350 seconds 
+GIIB-IIIA 200-250
POST Procedural No heparin
Sheath removal ≤150-180sec
Heparin reversal
100 Unit=1mg of Protamin Sulphate IV bolus
Manual aspiration thrombectomy
• 1.Microvascular function improves
• 2.Decrease death
• 3.MCE
I IIa IIb III
 Cardiac death and reinfarction after 1 year in the Thrombus Aspiration during
Percutaneous coronary intervention in Acute myocardial infarction Study (TAPAS):
a 1-year follow-up study. Lancet. 2008;371:1915–20
Intracoronary abciximab and aspiration thrombectomy in patients with large
anterior myocardial infarction: the INFUSE-AMI randomized trial. JAMA. 2012;307:
1817–26
No reduction infarction size in large AWMI
Culprit vs. Bystanders
Culprit vs. Bystanders
PCI should not be performed in a noninfarct artery at the time of
primary PCI in patients with STEMI who are hemodynamically
stable(2013 STEMI guideline).
I IIa IIb III
Preventive Angioplasty in Myocardial Infarction=PRAMI
2008 through 2013, at five centers in UK
465(234/234)
Subsequent PCI for inducible ischemia/refractory angina
 composite of death/nonfatal MI/refractory angina
 significantly reduced the risk of adverse cardiovascular events,
as compared with PCI limited to the infarct artery
STENTS
BMS/DES is useful
I IIa IIb III
BMS:High bleeding risk/noncomply with 1 year of DAPT/
anticipated invasive or surgical procedures in the coming year
I IIa IIb III
DES should not be used if unable to tolerate/comply with a
prolonged course of DAPT.
I IIa IIb III
Harm
POBA vs. BMS
 tenting further reduced subsequent TLR but not
shown a survival advantage
1. Stone GW et al. Comparison of angioplasty with stenting,
with or without abciximab, in acute myocardial infarction. N Engl J Med
2002;346:957-66
2. Grines CL, Cox DA, Stone GW, et al. Coronary angioplasty with or without
stent
implantation for acute myocardial infarction. Stent primary angioplasty in
myocardial
infarction study group. N Engl J Med 1999;341:1949-56.
BMS vs. DES
DES greater reduction in TLR BUT not associated
with improved survival because added late ST
Stone GW et al. Paclitaxel-eluting stents versus bare-metal stents in acute
myocardial infarction. N Engl J Med 2009;360:1946-59.
Brar SS et al. Use of drug-eluting stents in acute myocardial infarction: a
systematic review and meta-analysis. J Am Coll Cardiol 2009;53:1677-89.
TYPHOON, PASSION, SESAMI, DEDICATION, and HORIZONS AMI
DES for STEMI
• TVR reduction >>BMS
• No extra stent thrombosis with DAP
• PCI with DES is not mandatory in STEM
• BMS may be preferable in cases in which comorbid
conditions, compliance, or financial means may
interfere with the required duration of dual-
antiplatelet therapy after DES placement
POBA vs.BMS vs. DES(G1/G2)
Keeping to right is
right
BMS Vs DES( G1)
• no significant difference in mortality, (8.5 versus 10.2
percent; HR 0.85,(95% CI 0.70-1.04).
• TLR was lower with DES (12.7 versus 20.1 percent; HR 0.57, 95% CI
0.50-0.66).
• No Δ in the cumulative rate of ST (5.8 versus 4.3 percent; HR 1.13, 95% CI
0.86-1.47). VLS (events after two years) was higher for DES (HR 2.81, 95%
CI 1.28-6.19).
• No Δ in the cumulative rate of reinfarction (9.4 versus 5.9 percent; HR
1.12, 95% CI 0.88-1.41). 2Y- the rate significantly increased for DES (HR
2.06, 95% CI 1.22-3.49).
De Luca G, et al. DES vs BMS in primary angioplasty: a pooled patient-level meta-a
BMS vs DES -G2
Cobalt-chromium everolimus-eluting stents (CoCr-EES)
• one-year risk of cardiac death/ MI was reduced with the former but not
the latter (odds ratio [OR] 0.63, 95% CI 0.42-0.92 and 0.86, 95% CI 0.50-
1.49).
• one-year risk TVR was reduced with the former but not the latter (OR 0.45,
95% CI 0.29-0.66 and 0.60, 95% CI 0.34-1.05).
• the one-year risk of definite stent thrombosis was reduced with the
former but not the latter (OR 0.32, 95% CI 0.11-0.78 and 0.44, 95% CI 0.12-
1.79).
• lower one-year rates of cardiac death or MI, definite stent thrombosis, and
target vessel revascularization
The COMFORTABLE AMI trial
• WITH Biolums as polymer the MCE FURTHER
REDUCED
Drug-eluting balloon plus BMS
• First human trial
• not significantly different between the DEB-BMS
and BMS groups
• Drug is paclitaxel
Belkacemi A, J Am Coll Cardiol. 2012 Jun;59(25):2327-37. Epub 2012 Apr
11.
Direct Stenting
• significantly lower rate of all-cause death
• Lesser no flow/slow flow
• Better myocardial preservation
HORIZON AMI
 Loubeyre C et al. A RCT of direct stenting with conventional stent implantation in selected patients with AMI . J Am Coll Cardiol
2002; 39:15.
Ly HQ et al. Angiographic and clinical outcomes associated with direct versus conventional stenting among patients treated with
fibrinolytic therapy for ST-elevation acute myocardial infarction. Am J Cardiol 2005; 95:383.
Antoniucci D, et al. Direct infarct artery stenting without predilation and no-reflow in patients with acute myocardial infarction.
Am Heart J 2001; 142:684.
 Bioresorbable vascular Scaffolds
• Safe
• Feasible
• Available Size, short expiry is limitation
• Not approved/not guide lined
• Long term result awaited
PRAGUE-19 Study,87 pts/3 yrs//started in 2012/Abbott vascular
Intra coronary IIB-IIIA
inhibitor(abciximab)
 Death+ reinfarction, p=0.03
 Death ,p=0.04)
 TVR ,p=0.045)
 Reinfarction; p=0.13
Raffaele Piccolo et al,Italy,Meta analysis,2012, Heart doi:10.1136/heartjnl-
2011-301101
Intracoronary Adenosine
• A bolus injection of intracoronary adenosine (900
micrograms in 5 mL of 0.9% sodium chloride
solution). Control patients received an intravenous
bolus injection of adenosine (900 micrograms in 20 
mL sodium chloride) during the procedure
• Elective intracoronary administration of high-dose
adenosine as adjunctive therapy to primary PCI
reduces MVO
INTRA CORONARY TLT
• 2.5 lakhs unit STK
• Improves no reflow
• Improves TFC
• EPICARDIAL coronary looks beautiful
• At 6 months ,no gain add to viable myocardium
Murat Sezer et al, Turkey, N Engl J Med 2007; 356:1823-1834,
Date of download:
9/28/2013
Copyright © The American College of Cardiology.
All rights reserved.
From: Effect of Intracoronary Streptokinase Administered Immediately After Primary Percutaneous Coronary
Intervention on Long-Term Left Ventricular Infarct Size, Volumes, and Function
J Am Coll Cardiol. 2009;54(12):1065-1071. doi:10.1016/j.jacc.2009.04.083
Intracoronary hyperoxemic
reperfusion therapy
• Safe and well tolerated
Dixon SR et al,Pilot study, J Am Coll Cardiol. 2002;39(3):387
Ischemic conditioning
• Ischemic preconditioning
• Ischemic post conditioning confer benefit
• Remote Ischemic conditioning
30sec-1min-30sec-1min-30sec
Kloner RA, Jennings RB.
Suboptimal reperfusion after
PPCI/Complication
 Persistent stenosis or thrombosis
 Coronary dissection
 Intramural hematoma
 Side branch occlusion
 Coronary spasm
 Distal macroembolism
 Acute stent thrombosis
 No-reflow phenomenon
 Reperfusion injury
 Capillary blistering and edema of endothelial cells
 Edema and swelling of myocytes
PAMI:
Age ≥70 years
Diabetes
Longer time to reperfusion
Initial TIMI flow grade ≤1
Left ventricular ejection
fraction <50 percent
Ventricular Arrhythmias
• Immediate defibrillation or cardioversion for VF or
pulseless sustained VT,
• Early (within 24 hours of presentation)
administration of beta blockers.
• The prophylactic use of lidocaine is not
recommended.
• VPC, NSVT not associated with hemodynamic
compromise, and AIVR are not indicative of
increased SCD risk needs less attention.
No reflow phenomenon
• 10 – 30 %
• Influences the long term results of PCI significantly.
• Minimised by NTG(25 microgram). Verapamil,
diltiazem, GpIIBIIIA inhibitors, nikorandil(IONA),
thrombectomy, intracoronary STK, ischemic post
conditioning.
Rescue CABG < 3%
Aspirin should not be withheld
Short-acting intravenous GP IIb/IIIa receptor antagonists
(eptifibatide, tirofiban) should be discontinued at least 2 to 4
hours before urgent CABG.
Clopidogrel or ticagrelor should be discontinued at least 24 hours
before urgent on-pump CABG, if possible.
I IIa IIb III
I IIa IIb III
I IIa IIb III
RESCUE CABG
Abciximab should be discontinued at least 12 hours before
urgent CABG.
Urgent off-pump CABG within 24 hours of clopidogrel or
ticagrelor administration might be considered, especially if the
benefits of prompt revascularization outweigh the risks of
bleeding.
Urgent CABG within 5 days of clopidogrel or ticagrelor
administration or within 7 days of prasugrel administration
might be considered, especially if the benefits of prompt
revascularization outweigh the risks of bleeding.
I IIa IIb III
I IIa IIb III
I IIa IIb III
Role of third antiplatlet
Yes you may add,but
bleeding matters
Sheath removal timing
• ACT <160 SEC
• SHEATH SIZE α compression time
• USE OF Group IIA-IIIB inhibitors
• After 6 hrs for femoral and 2 hours for Radial
Beware of Bleeding
Very Elderly (≥85 Years)
 Claessen et al. Primary percutaneous
coronary intervention for ST elevation
myocardial infarction in octogenarians: trends
and outcomes. Heart 2010;96:843–7
Danish Registry Supports
Primary PCI in Elderly STEMI
Patients-2013
Senior-PAMI-2005
Secondary prevention
• Beta Blockers: initiated in the first 24 hours
unless C/I
• Renin-Angiotensin-Aldosterone System
Inhibitors:within 24 hrs
• Lipid Management
Posthospitalization Plan of Care
•Prevent hospital readmissions
•Should be used to facilitate the transition to effective
•Outpatient care
I IIa IIb III
•Exercise-based cardiac rehabilitation
•Secondary prevention programs
I IIa IIb III
Posthospitalization Plan of Care
Medication adherence
Follow-up
Dietary and physical activities
Compliance with interventions for secondary prevention should
be provided to patients with STEMI.
No smoking
No secondhand smoke
I IIa IIb III
I IIa IIb III
CVD risk can begin before birth!!

More Related Content

What's hot

Pci or throm or pi in stemi best strategy(apicon 09022019)-final
Pci or throm or pi in stemi best strategy(apicon 09022019)-finalPci or throm or pi in stemi best strategy(apicon 09022019)-final
Pci or throm or pi in stemi best strategy(apicon 09022019)-finalDr.Vinod Sharma
 
CORONARY ARTERY PERFORATION DURING PCI
CORONARY ARTERY PERFORATION DURING PCICORONARY ARTERY PERFORATION DURING PCI
CORONARY ARTERY PERFORATION DURING PCIVishal Vanani
 
Cardiac resynchronization therapy
Cardiac resynchronization therapyCardiac resynchronization therapy
Cardiac resynchronization therapyDr.Sayeedur Rumi
 
Coronary artery dissection and perforation
Coronary artery dissection and perforationCoronary artery dissection and perforation
Coronary artery dissection and perforationFuad Farooq
 
TAVR/TAVI/TRANCATHETER SAORTIC VALVE REPLECEMENT
TAVR/TAVI/TRANCATHETER SAORTIC VALVE REPLECEMENTTAVR/TAVI/TRANCATHETER SAORTIC VALVE REPLECEMENT
TAVR/TAVI/TRANCATHETER SAORTIC VALVE REPLECEMENTDr Virbhan Balai
 
Bypass graft intervention2
Bypass graft intervention2Bypass graft intervention2
Bypass graft intervention2Dr Virbhan Balai
 
Guiding catheter in coronary intervention
Guiding catheter in coronary interventionGuiding catheter in coronary intervention
Guiding catheter in coronary interventionkefelegn Tadesse
 
No reflow and slow flow phenomenon during pci
No reflow and slow flow phenomenon during pciNo reflow and slow flow phenomenon during pci
No reflow and slow flow phenomenon during pcirahul arora
 
Cardiac resynchronization therapy
Cardiac resynchronization therapyCardiac resynchronization therapy
Cardiac resynchronization therapyRamachandra Barik
 
Ventricular arrhythmias
Ventricular arrhythmiasVentricular arrhythmias
Ventricular arrhythmiasarnab ghosh
 
Intraluminal coronary thrombus aspiration in patients with STEMI. Prof. Andre...
Intraluminal coronary thrombus aspiration in patients with STEMI. Prof. Andre...Intraluminal coronary thrombus aspiration in patients with STEMI. Prof. Andre...
Intraluminal coronary thrombus aspiration in patients with STEMI. Prof. Andre...Chaichuk Sergiy
 
Ischemia trial
Ischemia trialIschemia trial
Ischemia trialDrvasanthi
 
Evaluation and management of Pacemaker malfunction
Evaluation and management of Pacemaker malfunctionEvaluation and management of Pacemaker malfunction
Evaluation and management of Pacemaker malfunctionPRAVEEN GUPTA
 
Right heart catheterization
 Right heart catheterization Right heart catheterization
Right heart catheterizationToufiqur Rahman
 
Coronary artery dissection
Coronary artery dissectionCoronary artery dissection
Coronary artery dissectionAnirudh Allam
 

What's hot (20)

Pci or throm or pi in stemi best strategy(apicon 09022019)-final
Pci or throm or pi in stemi best strategy(apicon 09022019)-finalPci or throm or pi in stemi best strategy(apicon 09022019)-final
Pci or throm or pi in stemi best strategy(apicon 09022019)-final
 
CORONARY ARTERY PERFORATION DURING PCI
CORONARY ARTERY PERFORATION DURING PCICORONARY ARTERY PERFORATION DURING PCI
CORONARY ARTERY PERFORATION DURING PCI
 
Cardiac resynchronization therapy
Cardiac resynchronization therapyCardiac resynchronization therapy
Cardiac resynchronization therapy
 
Coronary artery dissection and perforation
Coronary artery dissection and perforationCoronary artery dissection and perforation
Coronary artery dissection and perforation
 
TAVR/TAVI/TRANCATHETER SAORTIC VALVE REPLECEMENT
TAVR/TAVI/TRANCATHETER SAORTIC VALVE REPLECEMENTTAVR/TAVI/TRANCATHETER SAORTIC VALVE REPLECEMENT
TAVR/TAVI/TRANCATHETER SAORTIC VALVE REPLECEMENT
 
Chronic total occlusion
Chronic total occlusionChronic total occlusion
Chronic total occlusion
 
Bypass graft intervention2
Bypass graft intervention2Bypass graft intervention2
Bypass graft intervention2
 
Guiding catheter in coronary intervention
Guiding catheter in coronary interventionGuiding catheter in coronary intervention
Guiding catheter in coronary intervention
 
No reflow and slow flow phenomenon during pci
No reflow and slow flow phenomenon during pciNo reflow and slow flow phenomenon during pci
No reflow and slow flow phenomenon during pci
 
Cardiac resynchronization therapy
Cardiac resynchronization therapyCardiac resynchronization therapy
Cardiac resynchronization therapy
 
Ventricular arrhythmias
Ventricular arrhythmiasVentricular arrhythmias
Ventricular arrhythmias
 
Intraluminal coronary thrombus aspiration in patients with STEMI. Prof. Andre...
Intraluminal coronary thrombus aspiration in patients with STEMI. Prof. Andre...Intraluminal coronary thrombus aspiration in patients with STEMI. Prof. Andre...
Intraluminal coronary thrombus aspiration in patients with STEMI. Prof. Andre...
 
Pci vs cabg
Pci vs cabg    Pci vs cabg
Pci vs cabg
 
Ischemia trial
Ischemia trialIschemia trial
Ischemia trial
 
Evaluation and management of Pacemaker malfunction
Evaluation and management of Pacemaker malfunctionEvaluation and management of Pacemaker malfunction
Evaluation and management of Pacemaker malfunction
 
Stent thrombosis
Stent thrombosisStent thrombosis
Stent thrombosis
 
Stent Thrombosis
Stent ThrombosisStent Thrombosis
Stent Thrombosis
 
Management of no reflow
Management of no reflowManagement of no reflow
Management of no reflow
 
Right heart catheterization
 Right heart catheterization Right heart catheterization
Right heart catheterization
 
Coronary artery dissection
Coronary artery dissectionCoronary artery dissection
Coronary artery dissection
 

Similar to Primary Percutaneus coronary intervention

Intervention treatment for acs
Intervention treatment for acsIntervention treatment for acs
Intervention treatment for acsKyaw Win
 
STEMI – My Approach 2010
STEMI – My Approach 2010STEMI – My Approach 2010
STEMI – My Approach 2010ishakansari
 
FIBRINOLYTIC THERAPY.pptx
FIBRINOLYTIC THERAPY.pptxFIBRINOLYTIC THERAPY.pptx
FIBRINOLYTIC THERAPY.pptxdrsbansal2000
 
SYMCARD - Antiplatelet in ACS.pptx
SYMCARD - Antiplatelet in ACS.pptxSYMCARD - Antiplatelet in ACS.pptx
SYMCARD - Antiplatelet in ACS.pptxyansalvianto
 
Primary PCI: State of the art. Petr Widimsky
Primary PCI: State of the art. Petr WidimskyPrimary PCI: State of the art. Petr Widimsky
Primary PCI: State of the art. Petr WidimskyChaichuk Sergiy
 
Role of More Potent Antiplatelet in ACS Management
Role of More Potent Antiplatelet in ACS ManagementRole of More Potent Antiplatelet in ACS Management
Role of More Potent Antiplatelet in ACS ManagementPERKI Pekanbaru
 
Cardiogenic shock following acute MI
Cardiogenic shock following acute MICardiogenic shock following acute MI
Cardiogenic shock following acute MIDr. Lokesh Khandelwal
 
Cardiogenic shock
Cardiogenic shockCardiogenic shock
Cardiogenic shockGOPAL GHOSH
 
STEMI - Cath Lab
STEMI - Cath LabSTEMI - Cath Lab
STEMI - Cath Labishakansari
 
Management of LMCA ds
Management of LMCA dsManagement of LMCA ds
Management of LMCA dsRohitWalse2
 
Pci vs optimal medical therapy in chronic stable angina
Pci vs optimal medical therapy in chronic stable anginaPci vs optimal medical therapy in chronic stable angina
Pci vs optimal medical therapy in chronic stable anginaDr. Lokesh Khandelwal
 
New Option of Antiplatelet and Controversies in ACS Treatment
New Option of Antiplatelet and Controversies in ACS TreatmentNew Option of Antiplatelet and Controversies in ACS Treatment
New Option of Antiplatelet and Controversies in ACS TreatmentPERKI Pekanbaru
 
New perspectives in CLI - prof. Giancarlo Biamino
New perspectives in CLI - prof. Giancarlo BiaminoNew perspectives in CLI - prof. Giancarlo Biamino
New perspectives in CLI - prof. Giancarlo Biaminopiodof
 

Similar to Primary Percutaneus coronary intervention (20)

Intervention treatment for acs
Intervention treatment for acsIntervention treatment for acs
Intervention treatment for acs
 
STEMI – My Approach 2010
STEMI – My Approach 2010STEMI – My Approach 2010
STEMI – My Approach 2010
 
Thromboectomy trial
Thromboectomy trialThromboectomy trial
Thromboectomy trial
 
FIBRINOLYTIC THERAPY.pptx
FIBRINOLYTIC THERAPY.pptxFIBRINOLYTIC THERAPY.pptx
FIBRINOLYTIC THERAPY.pptx
 
SYMCARD - Antiplatelet in ACS.pptx
SYMCARD - Antiplatelet in ACS.pptxSYMCARD - Antiplatelet in ACS.pptx
SYMCARD - Antiplatelet in ACS.pptx
 
Primary PCI: State of the art. Petr Widimsky
Primary PCI: State of the art. Petr WidimskyPrimary PCI: State of the art. Petr Widimsky
Primary PCI: State of the art. Petr Widimsky
 
Chronic total occlusion
Chronic total occlusionChronic total occlusion
Chronic total occlusion
 
Role of More Potent Antiplatelet in ACS Management
Role of More Potent Antiplatelet in ACS ManagementRole of More Potent Antiplatelet in ACS Management
Role of More Potent Antiplatelet in ACS Management
 
Cardiogenic shock following acute MI
Cardiogenic shock following acute MICardiogenic shock following acute MI
Cardiogenic shock following acute MI
 
Acute STEMI Rx.pptx
Acute STEMI Rx.pptxAcute STEMI Rx.pptx
Acute STEMI Rx.pptx
 
Cardiogenic shock
Cardiogenic shockCardiogenic shock
Cardiogenic shock
 
STEMI - Cath Lab
STEMI - Cath LabSTEMI - Cath Lab
STEMI - Cath Lab
 
Management of LMCA ds
Management of LMCA dsManagement of LMCA ds
Management of LMCA ds
 
Pci vs optimal medical therapy in chronic stable angina
Pci vs optimal medical therapy in chronic stable anginaPci vs optimal medical therapy in chronic stable angina
Pci vs optimal medical therapy in chronic stable angina
 
New Option of Antiplatelet and Controversies in ACS Treatment
New Option of Antiplatelet and Controversies in ACS TreatmentNew Option of Antiplatelet and Controversies in ACS Treatment
New Option of Antiplatelet and Controversies in ACS Treatment
 
Angioplasty
AngioplastyAngioplasty
Angioplasty
 
Pacchioni A - AIMRADIAL 2014 - Cerebral microembolism
Pacchioni A - AIMRADIAL 2014 - Cerebral microembolismPacchioni A - AIMRADIAL 2014 - Cerebral microembolism
Pacchioni A - AIMRADIAL 2014 - Cerebral microembolism
 
Practice Intersection: How I Approach Thrombus in My Daily Clinical Practice
Practice Intersection: How I Approach Thrombus in My Daily Clinical Practice Practice Intersection: How I Approach Thrombus in My Daily Clinical Practice
Practice Intersection: How I Approach Thrombus in My Daily Clinical Practice
 
New perspectives in CLI - prof. Giancarlo Biamino
New perspectives in CLI - prof. Giancarlo BiaminoNew perspectives in CLI - prof. Giancarlo Biamino
New perspectives in CLI - prof. Giancarlo Biamino
 
Wivon
WivonWivon
Wivon
 

More from Ramachandra Barik

Intensive care of congenital heart disease.pptx
Intensive care of congenital heart disease.pptxIntensive care of congenital heart disease.pptx
Intensive care of congenital heart disease.pptxRamachandra Barik
 
Management of Hypetension.pptx
Management of Hypetension.pptxManagement of Hypetension.pptx
Management of Hypetension.pptxRamachandra Barik
 
CRISPR and cardiovascular diseases.pdf
CRISPR and cardiovascular diseases.pdfCRISPR and cardiovascular diseases.pdf
CRISPR and cardiovascular diseases.pdfRamachandra Barik
 
Pacemaker Pocket Infection After Splenectomy
Pacemaker Pocket Infection After SplenectomyPacemaker Pocket Infection After Splenectomy
Pacemaker Pocket Infection After SplenectomyRamachandra Barik
 
A Case of Device Closure of an Eccentric Atrial Septal Defect Using a Large D...
A Case of Device Closure of an Eccentric Atrial Septal Defect Using a Large D...A Case of Device Closure of an Eccentric Atrial Septal Defect Using a Large D...
A Case of Device Closure of an Eccentric Atrial Septal Defect Using a Large D...Ramachandra Barik
 
Trio of Rheumatic Mitral Stenosis, Right Posterior Septal Accessory Pathway a...
Trio of Rheumatic Mitral Stenosis, Right Posterior Septal Accessory Pathway a...Trio of Rheumatic Mitral Stenosis, Right Posterior Septal Accessory Pathway a...
Trio of Rheumatic Mitral Stenosis, Right Posterior Septal Accessory Pathway a...Ramachandra Barik
 
Anticoagulation therapy during pregnancy
Anticoagulation therapy during pregnancyAnticoagulation therapy during pregnancy
Anticoagulation therapy during pregnancyRamachandra Barik
 
Intracoronary optical coherence tomography
Intracoronary optical coherence tomographyIntracoronary optical coherence tomography
Intracoronary optical coherence tomographyRamachandra Barik
 
A roadmap for the human development
A roadmap for the human developmentA roadmap for the human development
A roadmap for the human developmentRamachandra Barik
 
Left ventricular false tendons
Left ventricular false tendonsLeft ventricular false tendons
Left ventricular false tendonsRamachandra Barik
 

More from Ramachandra Barik (20)

Willens's syndrome.pptx
Willens's syndrome.pptxWillens's syndrome.pptx
Willens's syndrome.pptx
 
Intensive care of congenital heart disease.pptx
Intensive care of congenital heart disease.pptxIntensive care of congenital heart disease.pptx
Intensive care of congenital heart disease.pptx
 
Management of Hypetension.pptx
Management of Hypetension.pptxManagement of Hypetension.pptx
Management of Hypetension.pptx
 
CRISPR and cardiovascular diseases.pdf
CRISPR and cardiovascular diseases.pdfCRISPR and cardiovascular diseases.pdf
CRISPR and cardiovascular diseases.pdf
 
Pacemaker Pocket Infection After Splenectomy
Pacemaker Pocket Infection After SplenectomyPacemaker Pocket Infection After Splenectomy
Pacemaker Pocket Infection After Splenectomy
 
Piccolo Duct Occluder.pdf
Piccolo Duct Occluder.pdfPiccolo Duct Occluder.pdf
Piccolo Duct Occluder.pdf
 
MISPLACED ECG LEADS.pptx
MISPLACED ECG LEADS.pptxMISPLACED ECG LEADS.pptx
MISPLACED ECG LEADS.pptx
 
A Case of Device Closure of an Eccentric Atrial Septal Defect Using a Large D...
A Case of Device Closure of an Eccentric Atrial Septal Defect Using a Large D...A Case of Device Closure of an Eccentric Atrial Septal Defect Using a Large D...
A Case of Device Closure of an Eccentric Atrial Septal Defect Using a Large D...
 
Arrythmia-IV.pptx
Arrythmia-IV.pptxArrythmia-IV.pptx
Arrythmia-IV.pptx
 
Arrythmia-III.pptx
Arrythmia-III.pptxArrythmia-III.pptx
Arrythmia-III.pptx
 
Arrythmia-II.pptx
Arrythmia-II.pptxArrythmia-II.pptx
Arrythmia-II.pptx
 
Arrythmia-I.pptx
Arrythmia-I.pptxArrythmia-I.pptx
Arrythmia-I.pptx
 
Trio of Rheumatic Mitral Stenosis, Right Posterior Septal Accessory Pathway a...
Trio of Rheumatic Mitral Stenosis, Right Posterior Septal Accessory Pathway a...Trio of Rheumatic Mitral Stenosis, Right Posterior Septal Accessory Pathway a...
Trio of Rheumatic Mitral Stenosis, Right Posterior Septal Accessory Pathway a...
 
Anticoagulation therapy during pregnancy
Anticoagulation therapy during pregnancyAnticoagulation therapy during pregnancy
Anticoagulation therapy during pregnancy
 
Coronary guidewire
Coronary guidewireCoronary guidewire
Coronary guidewire
 
Intracoronary optical coherence tomography
Intracoronary optical coherence tomographyIntracoronary optical coherence tomography
Intracoronary optical coherence tomography
 
Brugada syndrome
Brugada syndromeBrugada syndrome
Brugada syndrome
 
A roadmap for the human development
A roadmap for the human developmentA roadmap for the human development
A roadmap for the human development
 
Intra aortic balloon pump
Intra aortic balloon pumpIntra aortic balloon pump
Intra aortic balloon pump
 
Left ventricular false tendons
Left ventricular false tendonsLeft ventricular false tendons
Left ventricular false tendons
 

Recently uploaded

Range of Secondary Electrons and Electron Build-Up: Impact on Scatter in Homo...
Range of Secondary Electrons and Electron Build-Up: Impact on Scatter in Homo...Range of Secondary Electrons and Electron Build-Up: Impact on Scatter in Homo...
Range of Secondary Electrons and Electron Build-Up: Impact on Scatter in Homo...Dr. Dheeraj Kumar
 
Substance use disorder (drug addict ), Addiction
Substance use disorder (drug addict ), AddictionSubstance use disorder (drug addict ), Addiction
Substance use disorder (drug addict ), AddictionZeinabEmad3
 
ANATOMY OF THE CEREBRUM WITH CLINICAL ANATOMY.pptx
ANATOMY OF THE CEREBRUM WITH CLINICAL ANATOMY.pptxANATOMY OF THE CEREBRUM WITH CLINICAL ANATOMY.pptx
ANATOMY OF THE CEREBRUM WITH CLINICAL ANATOMY.pptxsiddharthroy26587
 
Methicillin-resistant Staphylococcus Aureus (MRSA)
Methicillin-resistant Staphylococcus Aureus (MRSA)Methicillin-resistant Staphylococcus Aureus (MRSA)
Methicillin-resistant Staphylococcus Aureus (MRSA)Ahmad Thanin
 
Spinal cord Gross anatomy with Clinical Anatomy.pptx
Spinal cord Gross anatomy with Clinical Anatomy.pptxSpinal cord Gross anatomy with Clinical Anatomy.pptx
Spinal cord Gross anatomy with Clinical Anatomy.pptxsiddharthroy26587
 
airway management recorded for S2.pptx
airway management  recorded  for S2.pptxairway management  recorded  for S2.pptx
airway management recorded for S2.pptxnakera38
 
Ayurveda research in Hypothyroidism, P
Ayurveda  research  in Hypothyroidism, PAyurveda  research  in Hypothyroidism, P
Ayurveda research in Hypothyroidism, PDr.Shalu Jain
 
Ten lessons learnt as anesthetist.pptx
Ten  lessons  learnt as anesthetist.pptxTen  lessons  learnt as anesthetist.pptx
Ten lessons learnt as anesthetist.pptxtusharchokshi1
 
Basic of Thyroid Hormone:- An In-depth Analysis
Basic of Thyroid Hormone:- An In-depth AnalysisBasic of Thyroid Hormone:- An In-depth Analysis
Basic of Thyroid Hormone:- An In-depth AnalysisAshishMaletha2
 
bleeding disorders 1 Dr.Nannika Pradhan
bleeding disorders 1  Dr.Nannika Pradhanbleeding disorders 1  Dr.Nannika Pradhan
bleeding disorders 1 Dr.Nannika Pradhanthesalberry
 
NECROSIS FOR MBBS FIRST YEAR STUDENTS MADE EASY.pptx
NECROSIS FOR MBBS FIRST YEAR STUDENTS MADE EASY.pptxNECROSIS FOR MBBS FIRST YEAR STUDENTS MADE EASY.pptx
NECROSIS FOR MBBS FIRST YEAR STUDENTS MADE EASY.pptxSizan Thapa
 
The Art and the Science of UK General Practice A historical review and timeli...
The Art and the Science of UK General Practice A historical review and timeli...The Art and the Science of UK General Practice A historical review and timeli...
The Art and the Science of UK General Practice A historical review and timeli...JakeMatthews12
 
Laryngeal papillomatosis .pdf ENT BY QUICKMEDTALK
Laryngeal papillomatosis .pdf ENT BY QUICKMEDTALKLaryngeal papillomatosis .pdf ENT BY QUICKMEDTALK
Laryngeal papillomatosis .pdf ENT BY QUICKMEDTALKQuick MedTalk
 
SGK BỆNH LÝ GOUT YHN hay lắm nha aaaa.pdf
SGK BỆNH LÝ GOUT YHN hay lắm nha aaaa.pdfSGK BỆNH LÝ GOUT YHN hay lắm nha aaaa.pdf
SGK BỆNH LÝ GOUT YHN hay lắm nha aaaa.pdfHongBiThi1
 
HERPES SIMPLEX VIRUS 12032019 TUESDAY pptx
HERPES SIMPLEX VIRUS 12032019 TUESDAY  pptxHERPES SIMPLEX VIRUS 12032019 TUESDAY  pptx
HERPES SIMPLEX VIRUS 12032019 TUESDAY pptxPulkitMittal54
 
ANATOMY OF CEREBELLUM With Clinical Anatomy.pptx
ANATOMY OF CEREBELLUM With Clinical Anatomy.pptxANATOMY OF CEREBELLUM With Clinical Anatomy.pptx
ANATOMY OF CEREBELLUM With Clinical Anatomy.pptxsiddharthroy26587
 
Brief introduction to information ecosystem x public health.pptx
Brief introduction to information ecosystem x public health.pptxBrief introduction to information ecosystem x public health.pptx
Brief introduction to information ecosystem x public health.pptxTina Purnat
 
Tracheostomy .pdf ENT by QuickMedTALK. getting things done on time
Tracheostomy .pdf ENT by QuickMedTALK. getting things done on timeTracheostomy .pdf ENT by QuickMedTALK. getting things done on time
Tracheostomy .pdf ENT by QuickMedTALK. getting things done on timeQuick MedTalk
 
ANTIPERSPIRANTS AND DEODORANTS : MECHANISM OF ACTION
ANTIPERSPIRANTS AND DEODORANTS : MECHANISM OF ACTIONANTIPERSPIRANTS AND DEODORANTS : MECHANISM OF ACTION
ANTIPERSPIRANTS AND DEODORANTS : MECHANISM OF ACTIONojaswinihemane
 

Recently uploaded (20)

Range of Secondary Electrons and Electron Build-Up: Impact on Scatter in Homo...
Range of Secondary Electrons and Electron Build-Up: Impact on Scatter in Homo...Range of Secondary Electrons and Electron Build-Up: Impact on Scatter in Homo...
Range of Secondary Electrons and Electron Build-Up: Impact on Scatter in Homo...
 
Substance use disorder (drug addict ), Addiction
Substance use disorder (drug addict ), AddictionSubstance use disorder (drug addict ), Addiction
Substance use disorder (drug addict ), Addiction
 
ANATOMY OF THE CEREBRUM WITH CLINICAL ANATOMY.pptx
ANATOMY OF THE CEREBRUM WITH CLINICAL ANATOMY.pptxANATOMY OF THE CEREBRUM WITH CLINICAL ANATOMY.pptx
ANATOMY OF THE CEREBRUM WITH CLINICAL ANATOMY.pptx
 
Methicillin-resistant Staphylococcus Aureus (MRSA)
Methicillin-resistant Staphylococcus Aureus (MRSA)Methicillin-resistant Staphylococcus Aureus (MRSA)
Methicillin-resistant Staphylococcus Aureus (MRSA)
 
Spinal cord Gross anatomy with Clinical Anatomy.pptx
Spinal cord Gross anatomy with Clinical Anatomy.pptxSpinal cord Gross anatomy with Clinical Anatomy.pptx
Spinal cord Gross anatomy with Clinical Anatomy.pptx
 
airway management recorded for S2.pptx
airway management  recorded  for S2.pptxairway management  recorded  for S2.pptx
airway management recorded for S2.pptx
 
Ayurveda research in Hypothyroidism, P
Ayurveda  research  in Hypothyroidism, PAyurveda  research  in Hypothyroidism, P
Ayurveda research in Hypothyroidism, P
 
Ten lessons learnt as anesthetist.pptx
Ten  lessons  learnt as anesthetist.pptxTen  lessons  learnt as anesthetist.pptx
Ten lessons learnt as anesthetist.pptx
 
Basic of Thyroid Hormone:- An In-depth Analysis
Basic of Thyroid Hormone:- An In-depth AnalysisBasic of Thyroid Hormone:- An In-depth Analysis
Basic of Thyroid Hormone:- An In-depth Analysis
 
bleeding disorders 1 Dr.Nannika Pradhan
bleeding disorders 1  Dr.Nannika Pradhanbleeding disorders 1  Dr.Nannika Pradhan
bleeding disorders 1 Dr.Nannika Pradhan
 
NECROSIS FOR MBBS FIRST YEAR STUDENTS MADE EASY.pptx
NECROSIS FOR MBBS FIRST YEAR STUDENTS MADE EASY.pptxNECROSIS FOR MBBS FIRST YEAR STUDENTS MADE EASY.pptx
NECROSIS FOR MBBS FIRST YEAR STUDENTS MADE EASY.pptx
 
The Art and the Science of UK General Practice A historical review and timeli...
The Art and the Science of UK General Practice A historical review and timeli...The Art and the Science of UK General Practice A historical review and timeli...
The Art and the Science of UK General Practice A historical review and timeli...
 
Laryngeal papillomatosis .pdf ENT BY QUICKMEDTALK
Laryngeal papillomatosis .pdf ENT BY QUICKMEDTALKLaryngeal papillomatosis .pdf ENT BY QUICKMEDTALK
Laryngeal papillomatosis .pdf ENT BY QUICKMEDTALK
 
SGK BỆNH LÝ GOUT YHN hay lắm nha aaaa.pdf
SGK BỆNH LÝ GOUT YHN hay lắm nha aaaa.pdfSGK BỆNH LÝ GOUT YHN hay lắm nha aaaa.pdf
SGK BỆNH LÝ GOUT YHN hay lắm nha aaaa.pdf
 
HERPES SIMPLEX VIRUS 12032019 TUESDAY pptx
HERPES SIMPLEX VIRUS 12032019 TUESDAY  pptxHERPES SIMPLEX VIRUS 12032019 TUESDAY  pptx
HERPES SIMPLEX VIRUS 12032019 TUESDAY pptx
 
ANATOMY OF CEREBELLUM With Clinical Anatomy.pptx
ANATOMY OF CEREBELLUM With Clinical Anatomy.pptxANATOMY OF CEREBELLUM With Clinical Anatomy.pptx
ANATOMY OF CEREBELLUM With Clinical Anatomy.pptx
 
Brief introduction to information ecosystem x public health.pptx
Brief introduction to information ecosystem x public health.pptxBrief introduction to information ecosystem x public health.pptx
Brief introduction to information ecosystem x public health.pptx
 
Tracheostomy .pdf ENT by QuickMedTALK. getting things done on time
Tracheostomy .pdf ENT by QuickMedTALK. getting things done on timeTracheostomy .pdf ENT by QuickMedTALK. getting things done on time
Tracheostomy .pdf ENT by QuickMedTALK. getting things done on time
 
Oral disorders .pptx
Oral disorders .pptxOral disorders .pptx
Oral disorders .pptx
 
ANTIPERSPIRANTS AND DEODORANTS : MECHANISM OF ACTION
ANTIPERSPIRANTS AND DEODORANTS : MECHANISM OF ACTIONANTIPERSPIRANTS AND DEODORANTS : MECHANISM OF ACTION
ANTIPERSPIRANTS AND DEODORANTS : MECHANISM OF ACTION
 

Primary Percutaneus coronary intervention

  • 1. Primary PCI Prof A N Patnaik Dr RAMACHANDRA BARIK Dr Lalita Nemani
  • 2. Define  STEMI only  Urgent angioplasty(with/out stenting)- Preferably in ≤90min  No TLT before or parallel  Open the infarct—related
  • 3.  Delayed PCI PCI After TLT 1.Rescue(REACT/MERLIN/RESCU E) 2.Facilitated(BRAVE/HERO/CAPI TAL/WASTE/ASCEND) Of its kinds
  • 5. STEMI Thygesen K, Alpert JS, White HD, et al. Universal definition of myocardial infarction. Circulation 2007;116:2634-53.
  • 6. Today’s evening • Abbreviating time is everything 1.Best transfer Protocol 2. Reverse Paradox • PPCI vs. TLT • Who need it? • PPCI in Octagenerian • Set up 1.Your Lab 2.Surgical Back up
  • 7. Contd...... • Operator skill • Initial therapy in ICCU • Radial vs. Femoral • Optimal anticoagulation • POBA/ BMS/DES • Hardware • IABP/ECMO-When and its role
  • 8. Contd.... • In cath lab • After cathlab=ICCU • Predischarge triage • Finance • Take home message
  • 10. Time is muscle Every minute counts Gersh BJ, Stone GW, White HD, et al. Pharmacological facilitation of primary percutaneous coronary intervention foracute myocardial infarction: is the slope of the curve the shape of the future? JAMA 2005;293:979-86
  • 11. Terkelsen CJ, Sorensen JT, Maeng M, et al. Systemdelay and mortality among patients with STEMI treated with primary percutaneous coronary intervention. JAMA2010;304:763-71.
  • 12. Primary PCI vs. TLT Choice (TIMI)-3 Flow in 95% vs 54%(TLT) Gersh BJ et al. Pharmacological facilitation of PPCI for STEMI: is the slope of the curve the shape of the future? JAMA 2005;293:979-86 Stone GW et al. Comparison of angioplasty with stenting,with or without abciximab, in acute myocardial infarction. N Engl J Med 2002;346:957-66
  • 14. PAMI Trial-1997 POBA provides a small-to-moderate, short-term clinical advantage over TLT with t-PA. PPCI when it can be accomplished promptly at experienced centers, should be considered an excellent alternative method for myocardial reperfusion. The investigators and centers participating in the GUSTO IIb Angioplasty Substudy ,Cleveland Clinic,USA
  • 15. A 2003 meta-analysis 23 randomized trials 7739 patients  Reductions in short-term death (7% vs 9%, P 0.0002),  fatal reinfarction (3% vs 7%, P 0.0001),  stroke (1% vs 2%, P 0.0004) Keeley EC et al. Primary angioplasty versus intravenous thrombolytic therapy foracute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 2003;361:13-20
  • 16. But TLT is the invaluable in certain conditions because delay in opening artery causes • CHF/ readmissions/OPD visits increases  independently with mortality(HR/OR=1.1)  detrimental in age<65, presenting within 2 hours Death+ reinfarction+disabling stroke at 30 days was significantly < PCI in 2 of the studies, with a trend toward significance in the underpowered third study
  • 21. Evidence.. • MITRA STUDY(Maximal therapy in AMI) • SWISS STUDY • DANAMI II • SHOCK(Shock) • NRMI-II(CHF)
  • 23. Then what to choose?Then what to choose? “Reperfusion paradox” vs Best transfer protocol
  • 25. Initial management =MONA Oxygen  Aspirin Nitroglycerin Opioids(Morphine)
  • 31. Anticoagulants ‡The recommended ACT with planned GP IIb/IIIa receptor antagonist treatment is 200 to 250 s. §The recommended ACT with no planned GP IIb/IIIa receptor antagonist treatment is 250 to 300 s (HemoTec device) or 300 to 350 s (Hemochron device).
  • 32. Access No but you better understandNo but you better understand
  • 34. Shock • Killip IV • Ionotrope optimum • Control IV fluid • CPR • IABP/ECMO • LVAD • CABG
  • 35. IABP but use it!!!!!!!! • No Δ in infarct size at 3-5 days • No Δ in all cause death at 6 months Ohman EM, et al. Use of aortic counterpulsation to improve sustained coronary artery patency during AMI.RCT. The Randomized IABP Study Group. Circulation 1994. Stone GW et al, (PAMI-II) Trial Investigators. J Am Coll Cardiol 1997; 29:1459. Brodie BR et al,IABP, before PPCI reduces catheterization laboratory events in high-risk patients with AMI . Am J Cardiol 1999 Patel MR,et al. CRISP AMI Trial. JAMA 2011; 306:1329.
  • 36. Anticoagulation-ACT Anticoagulation ACT HEPARIN ONLY 250 to 350 seconds  +GIIB-IIIA 200-250 POST Procedural No heparin Sheath removal ≤150-180sec Heparin reversal 100 Unit=1mg of Protamin Sulphate IV bolus
  • 37. Manual aspiration thrombectomy • 1.Microvascular function improves • 2.Decrease death • 3.MCE I IIa IIb III  Cardiac death and reinfarction after 1 year in the Thrombus Aspiration during Percutaneous coronary intervention in Acute myocardial infarction Study (TAPAS): a 1-year follow-up study. Lancet. 2008;371:1915–20 Intracoronary abciximab and aspiration thrombectomy in patients with large anterior myocardial infarction: the INFUSE-AMI randomized trial. JAMA. 2012;307: 1817–26 No reduction infarction size in large AWMI
  • 39. Culprit vs. Bystanders PCI should not be performed in a noninfarct artery at the time of primary PCI in patients with STEMI who are hemodynamically stable(2013 STEMI guideline). I IIa IIb III Preventive Angioplasty in Myocardial Infarction=PRAMI 2008 through 2013, at five centers in UK 465(234/234) Subsequent PCI for inducible ischemia/refractory angina  composite of death/nonfatal MI/refractory angina  significantly reduced the risk of adverse cardiovascular events, as compared with PCI limited to the infarct artery
  • 40. STENTS BMS/DES is useful I IIa IIb III BMS:High bleeding risk/noncomply with 1 year of DAPT/ anticipated invasive or surgical procedures in the coming year I IIa IIb III DES should not be used if unable to tolerate/comply with a prolonged course of DAPT. I IIa IIb III Harm
  • 41. POBA vs. BMS  tenting further reduced subsequent TLR but not shown a survival advantage 1. Stone GW et al. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med 2002;346:957-66 2. Grines CL, Cox DA, Stone GW, et al. Coronary angioplasty with or without stent implantation for acute myocardial infarction. Stent primary angioplasty in myocardial infarction study group. N Engl J Med 1999;341:1949-56.
  • 42. BMS vs. DES DES greater reduction in TLR BUT not associated with improved survival because added late ST Stone GW et al. Paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction. N Engl J Med 2009;360:1946-59. Brar SS et al. Use of drug-eluting stents in acute myocardial infarction: a systematic review and meta-analysis. J Am Coll Cardiol 2009;53:1677-89. TYPHOON, PASSION, SESAMI, DEDICATION, and HORIZONS AMI
  • 43. DES for STEMI • TVR reduction >>BMS • No extra stent thrombosis with DAP • PCI with DES is not mandatory in STEM • BMS may be preferable in cases in which comorbid conditions, compliance, or financial means may interfere with the required duration of dual- antiplatelet therapy after DES placement
  • 44. POBA vs.BMS vs. DES(G1/G2) Keeping to right is right
  • 45. BMS Vs DES( G1) • no significant difference in mortality, (8.5 versus 10.2 percent; HR 0.85,(95% CI 0.70-1.04). • TLR was lower with DES (12.7 versus 20.1 percent; HR 0.57, 95% CI 0.50-0.66). • No Δ in the cumulative rate of ST (5.8 versus 4.3 percent; HR 1.13, 95% CI 0.86-1.47). VLS (events after two years) was higher for DES (HR 2.81, 95% CI 1.28-6.19). • No Δ in the cumulative rate of reinfarction (9.4 versus 5.9 percent; HR 1.12, 95% CI 0.88-1.41). 2Y- the rate significantly increased for DES (HR 2.06, 95% CI 1.22-3.49). De Luca G, et al. DES vs BMS in primary angioplasty: a pooled patient-level meta-a
  • 46. BMS vs DES -G2 Cobalt-chromium everolimus-eluting stents (CoCr-EES) • one-year risk of cardiac death/ MI was reduced with the former but not the latter (odds ratio [OR] 0.63, 95% CI 0.42-0.92 and 0.86, 95% CI 0.50- 1.49). • one-year risk TVR was reduced with the former but not the latter (OR 0.45, 95% CI 0.29-0.66 and 0.60, 95% CI 0.34-1.05). • the one-year risk of definite stent thrombosis was reduced with the former but not the latter (OR 0.32, 95% CI 0.11-0.78 and 0.44, 95% CI 0.12- 1.79). • lower one-year rates of cardiac death or MI, definite stent thrombosis, and target vessel revascularization
  • 47. The COMFORTABLE AMI trial • WITH Biolums as polymer the MCE FURTHER REDUCED
  • 48. Drug-eluting balloon plus BMS • First human trial • not significantly different between the DEB-BMS and BMS groups • Drug is paclitaxel Belkacemi A, J Am Coll Cardiol. 2012 Jun;59(25):2327-37. Epub 2012 Apr 11.
  • 49. Direct Stenting • significantly lower rate of all-cause death • Lesser no flow/slow flow • Better myocardial preservation HORIZON AMI  Loubeyre C et al. A RCT of direct stenting with conventional stent implantation in selected patients with AMI . J Am Coll Cardiol 2002; 39:15. Ly HQ et al. Angiographic and clinical outcomes associated with direct versus conventional stenting among patients treated with fibrinolytic therapy for ST-elevation acute myocardial infarction. Am J Cardiol 2005; 95:383. Antoniucci D, et al. Direct infarct artery stenting without predilation and no-reflow in patients with acute myocardial infarction. Am Heart J 2001; 142:684.
  • 50.  Bioresorbable vascular Scaffolds • Safe • Feasible • Available Size, short expiry is limitation • Not approved/not guide lined • Long term result awaited PRAGUE-19 Study,87 pts/3 yrs//started in 2012/Abbott vascular
  • 51. Intra coronary IIB-IIIA inhibitor(abciximab)  Death+ reinfarction, p=0.03  Death ,p=0.04)  TVR ,p=0.045)  Reinfarction; p=0.13 Raffaele Piccolo et al,Italy,Meta analysis,2012, Heart doi:10.1136/heartjnl- 2011-301101
  • 52. Intracoronary Adenosine • A bolus injection of intracoronary adenosine (900 micrograms in 5 mL of 0.9% sodium chloride solution). Control patients received an intravenous bolus injection of adenosine (900 micrograms in 20  mL sodium chloride) during the procedure • Elective intracoronary administration of high-dose adenosine as adjunctive therapy to primary PCI reduces MVO
  • 53. INTRA CORONARY TLT • 2.5 lakhs unit STK • Improves no reflow • Improves TFC • EPICARDIAL coronary looks beautiful • At 6 months ,no gain add to viable myocardium Murat Sezer et al, Turkey, N Engl J Med 2007; 356:1823-1834,
  • 54. Date of download: 9/28/2013 Copyright © The American College of Cardiology. All rights reserved. From: Effect of Intracoronary Streptokinase Administered Immediately After Primary Percutaneous Coronary Intervention on Long-Term Left Ventricular Infarct Size, Volumes, and Function J Am Coll Cardiol. 2009;54(12):1065-1071. doi:10.1016/j.jacc.2009.04.083
  • 55. Intracoronary hyperoxemic reperfusion therapy • Safe and well tolerated Dixon SR et al,Pilot study, J Am Coll Cardiol. 2002;39(3):387
  • 56. Ischemic conditioning • Ischemic preconditioning • Ischemic post conditioning confer benefit • Remote Ischemic conditioning 30sec-1min-30sec-1min-30sec Kloner RA, Jennings RB.
  • 57. Suboptimal reperfusion after PPCI/Complication  Persistent stenosis or thrombosis  Coronary dissection  Intramural hematoma  Side branch occlusion  Coronary spasm  Distal macroembolism  Acute stent thrombosis  No-reflow phenomenon  Reperfusion injury  Capillary blistering and edema of endothelial cells  Edema and swelling of myocytes PAMI: Age ≥70 years Diabetes Longer time to reperfusion Initial TIMI flow grade ≤1 Left ventricular ejection fraction <50 percent
  • 58. Ventricular Arrhythmias • Immediate defibrillation or cardioversion for VF or pulseless sustained VT, • Early (within 24 hours of presentation) administration of beta blockers. • The prophylactic use of lidocaine is not recommended. • VPC, NSVT not associated with hemodynamic compromise, and AIVR are not indicative of increased SCD risk needs less attention.
  • 59. No reflow phenomenon • 10 – 30 % • Influences the long term results of PCI significantly. • Minimised by NTG(25 microgram). Verapamil, diltiazem, GpIIBIIIA inhibitors, nikorandil(IONA), thrombectomy, intracoronary STK, ischemic post conditioning.
  • 60. Rescue CABG < 3% Aspirin should not be withheld Short-acting intravenous GP IIb/IIIa receptor antagonists (eptifibatide, tirofiban) should be discontinued at least 2 to 4 hours before urgent CABG. Clopidogrel or ticagrelor should be discontinued at least 24 hours before urgent on-pump CABG, if possible. I IIa IIb III I IIa IIb III I IIa IIb III
  • 61. RESCUE CABG Abciximab should be discontinued at least 12 hours before urgent CABG. Urgent off-pump CABG within 24 hours of clopidogrel or ticagrelor administration might be considered, especially if the benefits of prompt revascularization outweigh the risks of bleeding. Urgent CABG within 5 days of clopidogrel or ticagrelor administration or within 7 days of prasugrel administration might be considered, especially if the benefits of prompt revascularization outweigh the risks of bleeding. I IIa IIb III I IIa IIb III I IIa IIb III
  • 62. Role of third antiplatlet Yes you may add,but bleeding matters
  • 63. Sheath removal timing • ACT <160 SEC • SHEATH SIZE α compression time • USE OF Group IIA-IIIB inhibitors • After 6 hrs for femoral and 2 hours for Radial
  • 65. Very Elderly (≥85 Years)  Claessen et al. Primary percutaneous coronary intervention for ST elevation myocardial infarction in octogenarians: trends and outcomes. Heart 2010;96:843–7 Danish Registry Supports Primary PCI in Elderly STEMI Patients-2013 Senior-PAMI-2005
  • 66. Secondary prevention • Beta Blockers: initiated in the first 24 hours unless C/I • Renin-Angiotensin-Aldosterone System Inhibitors:within 24 hrs • Lipid Management
  • 67. Posthospitalization Plan of Care •Prevent hospital readmissions •Should be used to facilitate the transition to effective •Outpatient care I IIa IIb III •Exercise-based cardiac rehabilitation •Secondary prevention programs I IIa IIb III
  • 68. Posthospitalization Plan of Care Medication adherence Follow-up Dietary and physical activities Compliance with interventions for secondary prevention should be provided to patients with STEMI. No smoking No secondhand smoke I IIa IIb III I IIa IIb III
  • 69. CVD risk can begin before birth!!